ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

17 träffar

Bibliografisk träff 2015-01-01

Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.

Braeckman RA, Stirtan WG, Soni PN.

Clin Drug Investig · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s40261-014-0252-8

Bibliografisk träff 2014-12-17

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl.

Hassan A, Tajuddin N, Shaikh A.

Cardiol Ther · brief-report; journal article · DOI 10.1007/s40119-014-0032-9

Bibliografisk träff 2014-12-01

Icosapent ethyl: a review of its use in severe hypertriglyceridemia.

Kim ES, McCormack PL.

Am J Cardiovasc Drugs · review; journal article · DOI 10.1007/s40256-014-0099-7

Bibliografisk träff 2014-09-01

Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults.

Braeckman RA, Stirtan WG, Soni PN.

Drugs R D · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s40268-014-0053-9

Bibliografisk träff 2014-07-01

Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.

Braeckman RA, Stirtan WG, Soni PN.

Clin Drug Investig · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s40261-014-0194-1

Bibliografisk träff 2014-06-24

Icosapent ethyl for the treatment of severe hypertriglyceridemia.

Fares H, Lavie CJ, DiNicolantonio JJ, O'Keefe JH, Milani RV.

Ther Clin Risk Manag · review-article; review; journal article · DOI 10.2147/tcrm.s36983

Bibliografisk träff 2014-05-01

A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.

Castaldo RS.

Postgrad Med · journal article · DOI 10.3810/pgm.2014.05.2775

Bibliografisk träff 2014-02-02

Potential benefits of icosapent ethyl on the lipid profile: case studies.

Hilleman DE, Malesker MA.

Clin Med Insights Cardiol · journal article; case reports; case-report · DOI 10.4137/cmc.s13571

Bibliografisk träff 2013-11-05

Icosapent ethyl for treatment of elevated triglyceride levels.

Nelson SD, Munger MA.

Ann Pharmacother · review; journal article · DOI 10.1177/1060028013504079

Bibliografisk träff 2013-08-01

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN.

Prostaglandins Leukot Essent Fatty Acids · research support, non-u.s. gov't; journal article · DOI 10.1016/j.plefa.2013.07.005

Bibliografisk träff 2013-07-31

Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.

Weintraub H.

Atherosclerosis · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.atherosclerosis.2013.07.041

Bibliografisk träff 2013-07-09

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN.

Cardiovasc Diabetol · clinical trial, phase iii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1186/1475-2840-12-100

Bibliografisk träff 2013-05-24

Icosapent ethyl for the treatment of hypertriglyceridemia.

Ballantyne CM, Braeckman RA, Soni PN.

Expert Opin Pharmacother · journal article · DOI 10.1517/14656566.2013.798645

Bibliografisk träff 2013-02-01

Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN.

Am J Cardiovasc Drugs · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s40256-012-0002-3

Bibliografisk träff 2012-07-24

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.jacl.2012.07.001

Bibliografisk träff 2012-07-20

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.amjcard.2012.05.031

Bibliografisk träff 2012-06-01

A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial.

Jacobson TA.

Expert Rev Cardiovasc Ther · clinical trial, phase iii; comparative study; multicenter study; randomized controlled trial; journal article · DOI 10.1586/erc.12.56